February 11, 2015
The plaintiff suing Allergan Inc.'s board of directors for failing to properly consider Valeant Pharmaceuticals International Inc.'s takeover bid on Wednesday decided to voluntarily dismiss the derivative class action, citing Valeant's decision to withdraw its own offer.
November 13, 2014
Allergan Inc.'s board of directors was hit with a new shareholder derivative class action in California federal court Wednesday alleging they failed to properly consider Valeant Pharmaceuticals International Inc.'s takeover bid as the Botox maker continues merger talks with another potential buyer.